NYU Grossman School of Medicine offers a 12-month postdoctoral fellowship within the organizational skills training and ...

Actuate Therapeutics said its treatment for Ewing sarcoma was granted rare pediatric-disease designation from the Food and Drug Administration. Chief Executive Daniel Schmitt said early clinical data ...

Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in ...

Between 2019 and 2023, the market grew at a CAGR of 9%, driven by the rising health-consciousness of consumers, particularly millennial and Gen-Z parents. As precision nutrition technologies advance, ...

First patient dosed in Phase 1/Phase 2 LION-CS101 trial of AB-1003 in August 2023, with enrollment continuing; Askle ...